Moderna Announces Supply Agreement with Peru for 20 Million Doses of Its COVID-19 Vaccine

Rhea-AI Summary

Moderna (MRNA) announced a supply agreement with the government of Peru for 20 million doses of its COVID-19 vaccine, with delivery commencing in Q1 2022. The vaccine is not yet approved for use in Peru, and Moderna will seek regulatory approvals prior to distribution. Corinne Le Goff, Moderna's CCO, expressed appreciation for the agreement, emphasizing the company's commitment to address the pandemic globally. The press release includes forward-looking statements regarding regulatory processes and delivery timelines, noting associated risks and uncertainties.

Positive

• Secured supply agreement with Peru for 20 million vaccine doses.
• Delivery set to begin in the first quarter of 2022.

Negative

• Vaccine not currently approved for use in Peru.
• Regulatory approval processes present potential delays and risks.

Delivery to begin in the first quarter of 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a supply agreement with the government of Peru for 20 million doses of Moderna’s COVID-19 vaccine to begin delivery in the first quarter of 2022. The COVID-19 Vaccine Moderna is not currently approved for use in Peru, and the Company will work with regulators to pursue necessary approvals prior to distribution.

“We appreciate the support from the government of Peru with this supply agreement for doses of the Moderna COVID-19 vaccine,” said Corinne Le Goff, Pharm.D., M.B.A, Chief Commercial Officer of Moderna. “We are committed to making our vaccine available around the world as we seek to address the pandemic with our COVID-19 vaccine.”

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Company’s development of a vaccine to protect against the SARS-CoV-2 virus (mRNA-1273); the Company’s agreement to supply the vaccine to the government of Peru; plans to obtain regulatory approval for distribution of the vaccine in Peru; and the anticipated number of doses and timing for delivery of vaccine supply. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210924005337/en/

Moderna Contacts



Media:

Colleen Hussey

Director, Corporate Communications

617-335-1374

Colleen.Hussey@modernatx.com



Investors:

Lavina Talukdar

Senior Vice President & Head of Investor Relations

617-209-5834

Lavina.Talukdar@modernatx.com

Source: Moderna, Inc.

FAQ

What is the significance of Moderna's agreement with Peru regarding the COVID-19 vaccine?

Moderna has secured a supply agreement with Peru for 20 million doses of its COVID-19 vaccine, which is crucial for expanding vaccination efforts.

When will Moderna's COVID-19 vaccine be delivered to Peru?

Delivery of the 20 million doses is scheduled to begin in the first quarter of 2022.

Is Moderna's COVID-19 vaccine approved for use in Peru?

No, the vaccine is not currently approved for use in Peru, and Moderna will need to obtain necessary regulatory approvals.

What risks are associated with Moderna's vaccine supply agreement with Peru?

The risks include regulatory approval processes that may lead to delays in vaccine distribution.

What are the forward-looking statements made by Moderna in the press release?

The forward-looking statements include plans for regulatory approvals and anticipated timelines for vaccine delivery.